Abstracts tagged "Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss)"

Abstract Number: 1601 • ACR Convergence 2024
Changing Spectrum of Systemic Therapies for Eosinophilic Granulomatosis with Polyangiitis from 2006-2023
Lynn Fussner¹, Christian Pagnoux², David Cuthbertson³, Thomas Corbridge⁴, Nader Khalidi⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Rennie Rhee⁸, Philip Seo¹¹, Anat Shavit¹², Jared Silver¹³, Ulrich Specks¹⁴, Kenneth Warrington¹⁴, Michael Wechsler¹⁵ and Peter Merkel⁸, and for the Vasculitis Clinical Research Consortium, ¹The Ohio State University, Columbus, OH, ²Mount Sinai Hospital, Toronto, ON, Canada, ³University of South Florida, Tampa, FL, ⁴US Value Evidence and Outcomes, GSK, Durham, NC, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Moreland Hills, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Johns Hopkins University, Baltimore, MD, ¹²BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹³US Medical Affairs - Respiratory, GSK, Durham, ¹⁴Mayo Clinic, Rochester, MN, ¹⁵National Jewish Health, Denver, CO
Background/Purpose: The emergence of biologic therapies targeting eosinophils via the IL-5 pathway provided new options for treatment in eosinophilic granulomatosis with polyangiitis (EGPA). There has…
Abstract Number: 1604 • ACR Convergence 2024
Utilizing Machine Learning with Claims Data to Diagnose and Quantify the Prevalence of Eosinophilic Granulomatosis with Polyangiitis
Peter Merkel¹, Peter Baudy², Donna Carstens², Benjamin North³, Mahvish Danka³, Stephanie Roy³, Hanna Marshall³ and Geoffrey Chupp⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Respiratory & Immunology US Medical, AstraZeneca, Wilmington, ³IQVIA, Philadelphia, ⁴School of Medicine, Yale University, New Haven
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis that can present indolently. This can lead to a delay in diagnosis and treatment. This study…
Abstract Number: 1605 • ACR Convergence 2024
Characteristics of Relapses in Patients with Eosinophilic Granulomatosis with Polyangiitis
Peter Merkel¹, David Jayne², Ulrich Specks³, Christian Pagnoux⁴, Parameswaran Nair⁵, Nader Khalidi⁵, Arnaud Bourdin⁶, Lena Börjesson Sjö⁷, Sofia Necander⁷, Anat Shavit⁸, Claire Walton⁹ and Michael Wechsler¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²University of Cambridge, Cambridge, United Kingdom, ³Mayo Clinic, Rochester, MN, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada, ⁶Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, France, ⁷Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁸BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁰National Jewish Health, Denver, CO
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by asthma, eosinophilia, and small-to-medium size vessel vasculitis. In the Phase 3, double-blind,…
Abstract Number: 1606 • ACR Convergence 2024
Demographic and Treatment Patterns in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Analysis of US Claims and Clinical Data
Paul Dolin¹, Anat Shavit¹, Karina A. Keogh², Jennifer Rowell³, Chris Edmonds⁴, James M. Eudicone⁵, Amanda M. Moore⁶, Melissa Wilson⁷, Kinwei A. Chan⁶, Thomas Peer⁸ and Stephanie Y. Chen⁹, ¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ²Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic,, Rochester, MN, ³Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, ⁴Market Access and Pricing, AstraZeneca, Gaithersburg, MD, ⁵Real World Science and Analytics, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ⁶TriNetX, Cambridge, MA, ⁷TriNetX, Durham, NC, ⁸TriNetX, Farmington, NY, ⁹BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by chronic necrotizing vasculitis. Conventional therapy (oral glucocorticoids [OGC] ± immunosuppressants), mepolizumab, and…
Abstract Number: 1607 • ACR Convergence 2024
Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Sebastian Klapa¹, Sabrina Arnold², Antje Müller², Andreas Koch³, Anja Staehle⁴, Wataru Kähler³, Harry Heidecke⁵, Gabriela Riemekasten² and Peter Lamprecht², ¹University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, ²University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, ³Christian-Albrechts-University Kiel, Institute of Experimental Medicine, Kiel, Germany, ⁴University of Lübeck, Department of Rheumatology and Immunology, Lübeck, Germany, ⁵CellTrend GmbH, Luckenwalde, Germany
Background/Purpose: Complement activation has been shown to play an important role in the pathogenesis of the two major anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) variants,…
Abstract Number: 1608 • ACR Convergence 2024
Interstitial Lung Disease in ANCA-associated Vasculitis: A Retrospective Study of Clinical Characteristics, Radiographic Features, and Outcomes
Janelle Castellino¹, Matas Orentas², Joshua Moran³, Joshlean Fair¹, Yanyu Zhang⁴ and Aleksandra Bukiej⁵, ¹Rush University Medical Center, Chicago, IL, ²RUMC, Chicago, IL, ³Rush University Medical Center - IM Residency, Chicago, IL, ⁴Rush University Medical Center, Chicago, ⁵Rush University Medical Center, River Forest, IL
Background/Purpose: Interstitial lung disease (ILD) is a significant manifestation of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and…
Abstract Number: L14 • ACR Convergence 2023
Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study
Michael Wechsler¹, Parameswaran Nair², Benjamin Terrier³, Bastian Walz⁴, Arnaud Bourdin⁵, David Jayne⁶, David Jackson⁷, Florence Roufosse⁸, Lena Börjesson Sjö⁹, Ying Fan¹⁰, Maria Jison¹⁰, Christopher McCrae¹¹, Sofia Necander⁹, Anat Shavit¹², Claire Walton¹² and Peter Merkel¹³, ¹National Jewish Health, Denver, CO, ²McMaster University, Hamilton, ON, Canada, ³Cochin Hospital, Paris, France, ⁴University of Tübingen, Kirchheim-Teck, Germany, ⁵University of Montpellier, CHU Montpellier, INSERM, Montpellier, Montpellier, France, ⁶Addenbrooke's Hospital, Cambridge, United Kingdom, ⁷Guy's Severe Asthma Centre, School of Immunology & Microbial Sciences, King's College London,, London, United Kingdom, ⁸Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, ⁹Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁰Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gaithersburg, MD, ¹¹Translational Science & Experimental Medicine, Early Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ¹²BioPharmaceutials Medical, AstraZeneca, Cambridge, United Kingdom, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Eosinophilic inflammation is a key pathophysiological mechanism of eosinophilic granulomatosis with polyangiitis (EGPA). Oral glucocorticoids (OGCs) and immunosuppressants remain the basis for the standard…
Abstract Number: 2380 • ACR Convergence 2023
Renal Survival Rate of ANCA-associated Vasculitis in Korea: A Nationwide Population-Based Study Using Claims Data
Chan-Bum Choi¹, Jung-Min Shin², Nayeon Choi³ and Soorack Ryu³, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, South Korea, ³Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea
Background/Purpose: ANCA-associated vasculitis (AAV) is a rare systemic autoimmune disease with varying reports of incidence rates and clinical manifestations. Renal involvement is one of the…
Abstract Number: 0674 • ACR Convergence 2023
Efficacy and Safety of Mepolizumab During Maintenance Therapy in Patients with Eosinophilic Granulomatosis with Polyangiitis
Daiki Sakai¹, Kaichi Kaneko¹, Karin Furukawa², Mai Kawazoe², Yasuo Matsuzawa³ and Toshihiro Nanki², ¹Division of Rheumatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Japan, ³Division of Respiratory Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, hyper-eosinophilia, and progressive multiorgan organ involvement. Mepolizumab (MPZ) is a humanized monoclonal…
Abstract Number: 0675 • ACR Convergence 2023
Investigating the Impact of anti-IL5 Therapy in the Management of Relapsing and Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA); A Three Year Longitudinal Perspective and Beyond
allyson egan¹, Pasupathy Sivasothy² and David Jayne³, ¹Trinity Health Kidney Centre, Tallaght University Hospital, Ireland, Dublin, Ireland, ²Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, ³University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the randomized, placebo-controlled MIRRA trial for relapsing and refractory eosinophilic granulomatosis with polyangiitis (EGPA), adjuvant therapy with 300mg anti-IL5 mAB Mepolizumab [MEPO] for…
Abstract Number: 0676 • ACR Convergence 2023
Mepolizumab Can Achieve Glucocorticoid Discontinuation in Eosinophilic Granulomatosis with Polyangiitis Patients Regardless of IgE Levels: A Retrospective Study at a Single Center
Takashi Yamane¹ and Akira Hashiramoto², ¹Kakogawa Central City Hospital, Kakogawa, Japan, ²Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis associated with eosinophil infiltration and Anti-neutrophil cytoplasmic antibody (ANCA) production. Mepolizumab (MPZ), an anti-IL-5 monoclonal…
Abstract Number: 0677 • ACR Convergence 2023
Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan
SOKO KAWASHIMA¹, Yoshinori Komagata¹, Mitsumasa Kishimoto² and Shinya Kaname¹, ¹Kyorin University School of Medicine, Tokyo, Japan, ²Kyorin University School of Medicine, Yokohoma, Japan
Background/Purpose: Contrary to Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan or Asian countries. It is possible that therapeutic responses to EGPA with mepolizumab…
Abstract Number: 0678 • ACR Convergence 2023
Benralizumab in Eosinophilic Granulomatosis with Polyangiitis
Adrien Cottu¹, Matthieu Groh², Charlène Desaintjean³, Sylvain Marchand-Adam⁴, Loic Guillevin⁵, Xavier Puéchal⁶, Estibaliz Lazaro⁷, Maxime Samson⁸, Camille Taillé⁹, Cécile-Audrey Durel¹⁰, Elisabeth Diot¹¹, Sarah Nicolas¹¹, Laurent Guilleminault¹², Mikael Ebbo¹³, Pascal Cathébras¹⁴, Clairelyne Dupin⁹, Halil Yildiz¹⁵, Nabil Belfeki¹⁶, Gregory Pugnet¹⁷, Pierre Chauvin¹⁸, Stephane Jouneau¹⁹, François Lifermann²⁰, Jean-Philippe Martellosio²¹, Vincent Cottin²² and Benjamin Terrier²³, ¹Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ²National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, ³Department of Respiratory Diseases, Hôpital Louis Pradel, Lyon, France, ⁴CHRU Tours, service de pneumologie et d'explorations fonctionnelles respiratoires, Tours, France, ⁵University Paris Descartes, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁷Bordeaux Hospital University, Pessac, France, ⁸Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ⁹AP-HP, Bichat Hospital, Reference Center for Rare Pulmonary Diseases and University of Paris Cité, Inserm 1152, Paris, France, ¹⁰CHU Lyon, Lyon, France, ¹¹Service de médecine interne et immunologie clinique, CHU Tours, Tours, France, ¹²Department of respiratory and allergic diseases, Toulouse University Hospital Center, Toulouse, France, ¹³Aix Marseille Univ, APHM, hôpital de la Timone, Internal Medicine Department, Marseille, France, ¹⁴Department of Internal medicine, Hôpital Nord, CHU St Etienne, Saint-Etienne, France, ¹⁵Saint Luc Hospital, Bruxelles, Belgium, ¹⁶Service de Médecine Interne et Immunologie Clinique. Groupe Hospitalier Sud Île de France, Melun, France, ¹⁷CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ¹⁸Department of Respiratory Diseases, Rennes University Hospital, Rennes, France, ¹⁹Amicus, Boca Raton, FL, ²⁰Department of Internal Medicine, Centre Hospitalier de Dax, Dax, France, ²¹Service de médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France, ²²Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ²³Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Gucocorticoid (GC)-dependant asthma and ENT exacerbations may persist in more than 80% of eosinophilic granulomatosis with polyangiitis (EGPA). The MIRRA trial demonstrated the efficacy…
Abstract Number: 0854 • ACR Convergence 2023
Long-term Efficacy of Remission-induction Regimens for Eosinophilic Granulomatosis with Polyangiitis
Martin Dutertre¹, Gregory Pugnet², Claire De Moreuil³, Bernard Bonnotte⁴, YGAL BENHAMOU⁵, Dominique Chauveau⁶, Elisabeth Diot⁷, Pierre Duffau⁸, Nicolas Limal⁹, Antoine Néel¹⁰, GEOFFREY URBANSKI¹¹, Noémie Jourde-Chiche¹², Nicolas MARTIN SILVA¹³, Francois Maurier¹⁴, Arsène Mekinian¹⁵, Nicolas Schleinitz¹⁶, Felix ackermann¹⁷, Anne-Laure Fauchais¹⁸, Antoine Froissart¹⁹, Thomas Le Gallou²⁰, Yurdagul Uzunhan²¹, Jean-Francois Viallard²², Alice Berezne²³, laurent chiche²⁴, Bruno Crestani²⁵, Guillaume Direz²⁶, Cecile-Audrey DUREL²⁷, Pascal Godmer²⁸, Jean-Emmanuel Kahn²⁹, Marc Lambert³⁰, Mathilde de Menthon¹, Thomas Quemeneur³¹, Jacques Cadranel¹, Pierre Charles³², Antoine Dossier¹, Loic Guillevin³³, Xavier Puéchal³⁴ and Benjamin Terrier³⁵, ¹AP-HP, Paris, France, ²CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ³CHU de Brest, Brest, France, ⁴Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ⁵rouen university hospital, Rouen, France, ⁶Hôpital Le Tripode, Bordeaux, France, ⁷Service de médecine interne et immunologie clinique, CHU Tours, Tours, France, ⁸CHU Bordeaux, Bordeaux, France, ⁹AP-HP, Créteil, France, ¹⁰CHU de Nantes, Nantes, France, ¹¹CHU Angers, Angers, France, ¹²AP-HM, Marseille, France, ¹³CHU Caen, Caen, France, ¹⁴Hôpitaux privés de Metz, Vaux / Frankreich, France, ¹⁵Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, ¹⁶Aix Marseille university, AP-HM, Marseille, France, ¹⁷Hôpital Foch, Suresnes, France, ¹⁸Dupuytren Hospital, Limoges, France, ¹⁹CHI Créteil, Créteil, France, ²⁰CHU Rennes, Rennes, France, ²¹AP-HP, Bobigny, France, ²²CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France, ²³CH Annecy, Annecy, France, ²⁴Hopital Europeen, Marseille, France, ²⁵Hopital Bichat, Paris University, Paris, France, ²⁶CH Le Mans, Le Mans, France, ²⁷Hospices Civils de Lyon, Lyon, France, ²⁸CH Bretagne Atlantique, Vannes, France, ²⁹AP-HP, Suresnes Cedex, France, ³⁰CHRU Lille, Lille, France, ³¹CH Valenciennes, Valenciennes, France, ³²Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, ³³University Paris Descartes, Paris, France, ³⁴National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ³⁵Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The Rituximab in Eosinophilic Granulomatosis With Polyangiitis (REOVAS) trial compared rituximab (RTX) infusions to conventional strategy for remission-induction in eosinophilic granulomatosis with polyangiitis (EGPA).…
Abstract Number: 0856 • ACR Convergence 2023
Dupilumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Berengere Molina¹, Roberto Padoan², Maria Letizia Urban³, Pavel Novikov⁴, Marco Caminati⁵, Camille Taillé⁶, Antoine Néel⁷, Laurence Bouillet⁸, Paolo Fraticelli⁹, Nicolas Schleinitz¹⁰, Christine Christides¹¹, Laura Moi¹², Bertrand Godeau¹³, Ann Knight¹⁴, Jan Walter Schroeder¹⁵, Sylvain Marchand-Adam¹⁶, Helder Gil¹⁷, Vincent Cottin¹⁸, Cécile-Audrey Durel¹⁹, Elena Gelain²⁰, Boris Lerais²¹, Marc Ruivard²², Matthieu Groh²³, Maxime Samson²⁴, Luca Moroni²⁵, Jens Thiel²⁶, Anna Kernder²⁷, Jan Willem Cohen Tervaert²⁸, Giulia Costanzo²⁹, Marco Folci³⁰, Sonia Rizzello³¹, Pascal Cohen³², Giacomo Emmi³³ and Benjamin Terrier³⁴, ¹Cochin Hospital, Paris, France, ²Department of Medicine DIMED, University of Padova, Padova, Italy, ³Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁴Sechenov First Moscow State Medical University, Moscow, Russia, ⁵University of Verona, Verona, Italy, ⁶AP-HP, Bichat Hospital, Reference Center for Rare Pulmonary Diseases and University of Paris Cité, Inserm 1152, Paris, France, ⁷CHU Nantes, Nantes, France, ⁸Internal medicine department, Grenoble University Hospital, Grenoble, France, ⁹University Hospital Ospedali Riuniti, Ancona, Italy, ¹⁰Aix Marseille university, AP-HM, Marseille, France, ¹¹Avignon Hospital, Avignon, France, ¹²Valais Hospital, Sion, Switzerland, ¹³CHU Henri Mondor, Créteil, France, ¹⁴Uppsala University, Uppsala, Sweden, ¹⁵ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ¹⁶CHRU Tours, service de pneumologie et d'explorations fonctionnelles respiratoires, Tours, France, ¹⁷CHU Besancon, Besançon, France, ¹⁸Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹⁹CHU Lyon, Lyon, France, ²⁰Meyer Children's Hospital, Florence, Italy, ²¹Brest University Hospital, Brest, France, ²²CHU Clermont Ferrand, Clermont Ferrand, France, ²³National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, ²⁴Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²⁵San Raffaele Scientific Institute, Milan, Italy, ²⁶University Hospital Freiburg, Freiburg, Germany, ²⁷Heinrich-Heine-University Düsseldorf, Dusseldorf, Germany, ²⁸University of Alberta, Edmonton, AB, Canada, ²⁹University of Cagliari, Monserrato, Italy, ³⁰Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy, ³¹Careggi University Hospital, Florence, Italy, ³²CHU Cochin, Paris, France, ³³University of Florence, Florence, Italy, ³⁴Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitides characterized by asthma, blood and tissue eosinophilia and systemic manifestations. Glucocorticoids (GCs)-dependent asthma and/or disabling…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].